7.85
+1.805(+29.86%)
Currency In USD
Address
1185 Avenue of the Americas
New York City, NY 10036
United States of America
Phone
973 242 0005
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
December 08, 2020
| Name | Title | Pay | Year Born |
| Alan J. Tuchman | Chief Executive Officer & Director | 278,234 | 1947 |
| Daniel L. Alkon | President, Chief Scientific Officer & Director | 350,000 | 1942 |
| Robert Weinstein | Chief Financial Officer, Executive Vice President, Treasurer & Secretary | 565,876 | 1960 |
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.